Toward the development of science-based medicine:トランスレーショナル・リサーチの推進
小澤 敬也
特別講演
1. Aplastic anemia, telomere attrition, and the new telomeropathies
Neal S. Young
2. Maintenance therapy in lymphoma
Ulrich Jäger
3. 医学研究の要素とシステム：循環器研究の立場から
永井 良三
4. Therapy with mesenchymal stromal cells: Evolving concepts of action
Armand Keating
JSH学会賞受賞講演
Proposal of Niche Therapy
須田 年生
Presidential Symposium
Innovative Gene & Cell Therapy for Hematological Diseases
1）Chimeric antigen receptor（CAR）modified T cells as a novel approach to cancer immunotherapy：Initial promising clinical responses and future directions
Renier J. Brentjens
2）Gene therapy for hemophilia
Katherine A. High
3）Genome editing with engineered zinc finger nucleases
Philip D. Gregory
4）iPS cell research using large animals
Yutaka Hanazono
JSH-EHA Joint Symposium
Pathophysiology of Bone Marrow Failure Syndromes
1）Preferential activation of hematopoietic stem cells with genetic alterations in patients with acquired aplastic anemia
Shinji Nakao
2）The molecular basis of myelodysplastic syndromes and its clinical relevance
Mario Cazzola
3）Similarities and differences between hypoplastic refractory cytopenia and aplastic anemia in children
Seiji Kojima
4）The pathophysiology of PNH: Lessons from targeted therapy
Peter Hillmen
JSH-ASH Joint Symposium
Science-Based Medicine for Malignant Lymphoma
1）Molecular pathogenesis of B-cell lymphoma
Riccardo Dalla-Favera
2）Molecular characterization of T/NK cell malignancies
Masao Seto
3）Diffuse large B-cell lymphoma:Treatment decisions based on molecular features
Wyndham Wilson
4）Science-based management of adult T-cell leukemia-lymphoma
Kunihiro Tsukasaki
Asian Joint Symposium
1）Prognostic relevance of recurrent mutations in adult acute myeloid leukemia
Chirayu Udomsakdi Auewarakul
2）A mouse model bearing "conventional" knock-in of Npm1 mutation reveals myeloid expansion and implies a perturbation in hematopoietic microenvironment
Wen-Chien Chou
3）Targeting chemotherapy-resistant AML cells
Fumihiko Ishikawa
4）Immunotherapy utilizing haploidentical HCT and subsequent donor NK cell infusion in refractory acute leukemia
Kyoo-Hyung Lee
5）Allogeneic hematopoietic stem cell transplantation in China: Where we are and where to go
Xiao-jun Huang
シンポジウム 1
The Research Front Line of Immune Thrombocytopenia
1）Pathophysiology and diagnosis of primary immune thrombocytopenia
Yoshiaki Tomiyama
2）Current management of immune thrombocytopenia in Japan
Yoshitaka Miyakawa
3）Thrombopoietin mimetics for the treatment of ITP
David J. Kuter
4）Chronic immune thrombocytopenia as a disease with or without association of defined diseases in children
Masatoshi Takagi
5）Thrombocytopenia in the antiphospholipid syndrome
Ricard Cervera
シンポジウム 2
Co-sponsored：JCA（Japnanese Cancer Association）
Epigenomics of Hematopoiesis and Cancer
1）Role of the polycomb group proteins in the restriction of tumor development
Atsushi Iwama
2）H3K27 methylation regulators and their roles in acute leukemia
Iannis Aifantis
3）Regulation of histone modifications in hematopoietic and leukemic stem cells
Issei Kitabayashi
4）Epigenetic field defect and its formation mechanisms
Toshikazu Ushijima
5）Cancer epigenetics: New drugs and paradigms
Frank Lyko
シンポジウム 3
Co-sponsored：JSMO（Japanese Society of Medical Oncology）
Myeloid Malignancies in a New Era of Molecularly Targeted Therapy
1）Cancer stem cell research for innovative Cell-modifying technologies
Hideshi Ishii
2）DNA hydroxymethylation in hematologic malignancies
1）Clinical development of MSC for the treatment of steroid refractory acute GVHD in Japan
Katsuhiko Tachibana
2）Mesenchymal stem cells for treatment of Graft-Versus-Host Disease
Katarina Le Blanc
3）Regulation of hematopoiesis by mesenchymal stem cells
Yasuo Miura
4）Mesenchymal stem cells expand the spectrum of cell therapy
Edwin M. Horwitz
5）Mesenchymal stem cell-based therapy -bench to bed-
Akihiro Umezawa
シンポジウム 5
GVHD対策の最前線～非血縁者間末梢血幹細胞移植導入への対応～
1）基調講演 Peripheral blood stem cells versus bone marrow from unrelated donors: Results of blood and marrow transplant clinical trials network protocol 0201, a phase Ⅲ, prospective, randomized trial
Claudio Anasetti
2）日本国内の骨髄移植と末梢血幹細胞移植の比較
長藤 宏司
3）日本国内の非血縁者間末梢血幹細胞移植の現状
宮村 耕一
3）日本の急性GVHD治療の現状
村田 誠
4）日本国内のATGを用いたGVHD予防の現状
藤 重夫
シンポジウム 6
Multiple Myeloma: Topics in Basic Science Applicable to the Development of Novel Therapies
1）Origin of the myeloma initiating cells and development of its targeting therapies
Naoki Hosen
2）Intracellular targets of Immunomodulatory derivatives of thalidomide（IMiD®）
Suzanne Lentzsch
3）How to overcome the cell adhesion-mediated drug resistance in multiple myeloma
Yusuke Furukawa
4）Targeting the interplay between myeloma cells and the bone marrow microenvironment
Masahiro Abe
5）Targeting myeloma cells and their microenvironment
